Carotuximab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Carotuximab
Accession Number
DB06322
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description
Not Available
Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Carotuximab
  • Chimeric anti-CD105 antibody
External IDs
C-SN6J / DE-122 / TRC 105 / TRC-105 / TRC105
Categories
UNII
YB2EWE6139
CAS number
1268714-50-6

Pharmacology

Indication

Investigated for use/treatment in solid tumors.

Pharmacodynamics
Not Available
Mechanism of action

TRC105 is a first-in-class human chimeric monoclonal antibody that inhibits tumor growth by binding to CD105 (endoglin), a receptor over-expressed on proliferating endothelium that is required for angiogenesis (growth of new blood vessels). TRC105 has shown activity, as monotherapy or when combined with chemotherapy, in pre-clinical studies of breast and colorectal cancer. Pre-clinical data also indicate CD105 expression is increased following treatment of human cancer with anti-VEGF therapy. The target of TRC105 shares many features with the VEGF receptor. Most importantly, both the VEGF and CD105 receptors are essential for angiogenesis, in that deletion of either receptor prevents blood vessel formation in utero. [Traecon Pharmaceuticals Press Release]

TargetActionsOrganism
UEndoglinNot AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Carotuximab.
AbituzumabThe risk or severity of adverse effects can be increased when Carotuximab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Carotuximab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Carotuximab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Carotuximab.
AducanumabThe risk or severity of adverse effects can be increased when Carotuximab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Carotuximab.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Carotuximab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Carotuximab.
AlirocumabThe risk or severity of adverse effects can be increased when Carotuximab is combined with Alirocumab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
TRC105

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)2
1CompletedTreatmentAdult Solid Tumor1
1RecruitingTreatmentLung Cancers1
1, 2Active Not RecruitingTreatmentAdvanced Soft Tissue Sarcoma1
1, 2Active Not RecruitingTreatmentHepatocellular,Carcinoma1
1, 2Active Not RecruitingTreatmentRenal Cell Adenocarcinoma1
1, 2CompletedTreatmentAdenoma, Liver Cell / Hepatocellular,Carcinoma / Liver Neoplasms, Experimental / Neoplasms, Hepatic1
1, 2CompletedTreatmentAdult Anaplastic Astrocytoma / Adult Anaplastic Oligodendroglioma / Adult Giant Cell Glioblastoma / Adult Glioblastoma / Adult Gliosarcoma / Adult Mixed Glioma / Recurrent Adult Brain Neoplasm1
1, 2CompletedTreatmentAge-Related Macular Degeneration (ARMD)1
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)1
1, 2CompletedTreatmentMetastatic Castrate Resistant Prostate Cancer / Prostate Cancer1
1, 2Enrolling by InvitationTreatmentTumors, Solid1
1, 2RecruitingTreatmentCancer, Breast1
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedTreatmentCancer of the Ureter / Transitional Cell Carcinoma / Ureteral Cancer / Ureteral Neoplasms1
2CompletedTreatmentChoriocarcinoma1
2CompletedTreatmentClear Cell Renal Cell Carcinoma / Renal Cell Carcinoma Recurrent / Stage IV Renal Cell Cancer / Type 1 Papillary Renal Cell Carcinoma / Type 2 Papillary Renal Cell Carcinoma1
2CompletedTreatmentFallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Ovarian Cancer1
2CompletedTreatmentGlioblastoma Multiforme (GBM) / Glioblastomas1
2CompletedTreatmentHepatocellular Cancer / Hepatocellular,Carcinoma1
2RecruitingTreatmentAge-Related Macular Degeneration (ARMD)1
2TerminatedTreatmentChoriocarcinoma / Epithelioid Trophoblastic Tumor / Gestational Trophoblastic Neoplasia / Placental Site Trophoblastic Tumor1
2TerminatedTreatmentGlioblastoma Multiforme (GBM)1
3Active Not RecruitingTreatmentAdvanced Angiosarcoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Type ii transforming growth factor beta receptor binding
Specific Function
Major glycoprotein of vascular endothelium. Involved in the regulation of angiogenesis. May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors. Acts as...
Gene Name
ENG
Uniprot ID
P17813
Uniprot Name
Endoglin
Molecular Weight
70577.325 Da

Drug created on March 19, 2008 10:24 / Updated on June 04, 2019 06:23